4-(3-chlorophenoxy)-6,7-dimethoxyquinazoline

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-(3-chlorophenoxy)-6,7-dimethoxyquinazoline
• 英文别名: 4-(m-chlorophenoxy)-6.7-dimethoxyquinazoline；4-(3-Chloro-phenoxy)-6,7-dimethoxy-quinazoline
• 化学式: C₁₆H₁₃ClN₂O₃
• 分子量: 316.744
• InChiKey: XDUSWBSGDKRQAF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  53.5
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  2-氨基-4,5-二甲氧基苯甲酸 在 哌啶 、 sodium hydride 、 三氯氧磷 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 生成 4-(3-chlorophenoxy)-6,7-dimethoxyquinazoline
  参考文献：
  名称：

  The preparation and sar of 4-(anilino), 4-(phenoxy), and 4-(thiophenoxy)-quinazolines: Inhibitors of p56lck and EGF-R tyrosine kinase activity

  摘要：

  We report herein our preliminary results of a SAR study of quinazoline-based inhibitors of p56(lck) and EGF-R tyrosine kinase activity.(1) The most potent inhibitor of p56(lck) identified, RPR-108518A (10), has an IC50 of 0.50 mu M. The 3-chlorophenoxy- and 3-chlorothiophenoxy- derivatives 5 and 6 were also shown to be extremely potent EGF-R inhibitors. (C) 1997, Elsevier Science Ltd.

  DOI：

  10.1016/s0960-894x(97)00034-6

文献信息

• Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having
  申请人：Rhone-Poulenc Rorer Pharmaceuticals Inc.

  公开号：US05721237A1

  公开（公告）日：1998-02-24

  This invention relates to a method for the selective treatment of cell growth and differentiation characterized by activity of the human epidermal growth factor receptor type 2 (HER2). More specifically, this invention relates to the use of substituted or unsubstituted mono- or bi-cyclic aryl, heteroaryl, cycloalkyl or heterocycloalkyl compounds in selectively regulating cell growth. Pharmaceutical compositions useful for the selective treatment of cell growth and differentiation are also described.

  本发明涉及一种针对人表皮生长因子受体类型2（HER2）活性的细胞生长和分化的选择性治疗方法。更具体地，本发明涉及使用取代或未取代的单环或双环芳基、杂芳基、环烷基或杂环烷基化合物，在选择性调节细胞生长方面的应用。还描述了对细胞生长和分化进行选择性治疗的药物组合物。
• Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor
  申请人：Rhone-Poulenc Rorer Pharmaceuticals, Inc.

  公开号：US05714493A1

  公开（公告）日：1998-02-03

  This invention relates to the treatment of intimation in a patient suffering from such disorder. More specifically, the invention relates to mono- and/or bicyclic aryl or heteroaryl quinazoline compounds in the treatment of inflammation.

  本发明涉及治疗患有炎症障碍的患者的方法。更具体地说，本发明涉及使用单环和/或双环芳基或杂环芳基喹唑啉类化合物治疗炎症。
• Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
  申请人：——

  公开号：US20040014774A1

  公开（公告）日：2004-01-22

  This invention relates to the modulation and/or inhibition of cell signaling, cell proliferation, cell inflammatory response, the control of abnormal cell growth and cell reproduction. More specifically, this invention relates to the use of mono- and/or bicyclic aryl or heteroaryl quinazoline compounds in inhibiting cell proliferation, including compounds which are useful protein tyrosine kinase (PTK) inhibitors. The method of treating cell proliferation and/or differentiation or mediator release using said quinazoline compounds and their use in pharmaceutical compositions is described.

  本发明涉及细胞信号传导、细胞增殖、细胞炎症反应、控制异常细胞生长和细胞繁殖的调节和/或抑制。更具体地，本发明涉及使用单环和/或双环芳基或杂芳基喹唑啉化合物抑制细胞增殖，包括对蛋白酪氨酸激酶（PTK）的抑制剂有用的化合物。描述了使用所述喹唑啉化合物治疗细胞增殖和/或分化或介质释放的方法以及它们在制药组合物中的应用。
• Quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
  申请人：Aventis Pharmaceuticals Products Inc.

  公开号：EP1488792A2

  公开（公告）日：2004-12-22

  This invention relates to the modulation and/or inhibition of cell signaling, cell proliferation, cell inflammatory response, the control of abnormal cell growth and cell reproduction. More specifically, this invention relates to the use of quinazoline compounds in inhibiting cell proliferation, including compounds which are useful protein tyrosine kinase (PTK) inhibitors. The method of treating cell proliferation and/or differentiation or mediator release using said quinazoline compounds and their use in pharmaceutical compositions is described.

  本发明涉及细胞信号、细胞增殖、细胞炎症反应、异常细胞生长控制和细胞繁殖的调节和/或抑制。更具体地说，本发明涉及喹唑啉化合物在抑制细胞增殖方面的用途，包括作为有用的蛋白酪氨酸激酶（PTK）抑制剂的化合物。本发明描述了使用所述喹唑啉化合物治疗细胞增殖和/或分化或介质释放的方法及其在药物组合物中的用途。
• USRE037650E1
  申请人：——

  公开号：——

  公开（公告）日：——